Browse Category

NYSE:FTS News 16 December 2025

Newfoundland Power and Mysa Launch takeCHARGE Smart Thermostat Pilot: How NL Households Can Earn Up to $140 for Cutting Peak Demand

Newfoundland Power and Mysa Launch takeCHARGE Smart Thermostat Pilot: How NL Households Can Earn Up to $140 for Cutting Peak Demand

ST. JOHN’S, N.L. — A new winter pilot in Newfoundland and Labrador is offering cash-like rewards to households that help reduce electricity demand when the provincial grid is under the most pressure. Newfoundland Power, working with St. John’s-based smart thermostat company Mysa, is rolling out a limited-capacity “demand response” program aimed at trimming peak-time electricity use—primarily from electric baseboard heating—through small, automated temperature adjustments that participants can override at any time. Alapbs+2TakeCHARGE+2 The initiative is being delivered through takeCHARGE, the energy efficiency partnership backed by Newfoundland and Labrador Hydro and Newfoundland Power. It’s designed to test whether coordinated, short-term reductions

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop